Treatment of acute myeloid leukemia during the second and third trimesters of pregnancy

Pharmacotherapy

Volumn 25, Issue 8, 2005, Pages 1134-1140

  Niedermeier, Dawn M ^a   Frei Lahr, Debra A ^a,b   Hall, Philip D ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Acute myeloid leukemia; AML; Second trimester pregnancy; Stem cell mobilization

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CD33 ANTIGEN; CD34 ANTIGEN; CLINDAMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID; TIOGUANINE; VINCRISTINE;

ACROCYANOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD DISEASE; BONE MARROW APLASIA; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CASE REPORT; CAUSE OF DEATH; CLINICAL PROTOCOL; CONGENITAL HEART MALFORMATION; CONGESTIVE CARDIOMYOPATHY; CRANIOFACIAL MALFORMATION; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; FETUS DEATH; FETUS ECHOGRAPHY; FETUS MALFORMATION; FETUS OUTCOME; GRAM POSITIVE BACTERIUM; GROWTH RETARDATION; HEART ATRIUM SEPTUM DEFECT; HEART DILATATION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HUMAN TISSUE; HYDRONEPHROSIS; HYPOGLYCEMIA; HYPONATREMIA; INFERTILITY; INTRAUTERINE GROWTH RETARDATION; IRIS DISEASE; JAW MALFORMATION; LEUKAPHERESIS; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIMB MALFORMATION; LYMPHOCYTE COUNT; MACROGNATHIA; MENTAL DEFICIENCY; METASTASIS; NEUROBLASTOMA; PATENT DUCTUS ARTERIOSUS; PSEUDOMONAS; PSEUDOMONAS VESICULARIS; REMISSION; RISK BENEFIT ANALYSIS; SECOND TRIMESTER PREGNANCY; SEIZURE; SEPTICEMIA; SIDE EFFECT; STEM CELL MOBILIZATION; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; THYROID CANCER;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CESAREAN SECTION; CYTARABINE; FEMALE; FETAL MONITORING; FILGRASTIM; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; STEM CELLS;

EID: 23244439360     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.8.1134     Document Type: Article

References (25)

1. Aviles A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2001;2:173-7.
2. Claahsen HL, Semmekrot BA, Van Dongen PWJ, Mattijssen V. Successful fetal outcome after exposure to idarubicin and cytosine-arabincside during the second trimester of pregnancy: a case report. Am J Perinatol 1998;15:295-7.
3. Reynoso EE, Shepherd FA, Messner HA, Farquharson HA, Garvey MB, Baker MA. Acute leukemia during pregnancy: the Toronto leukemia study group experience with long-term follow-up of children exposed to in utero chemotherapeutic agents. J Clin Oncol 1987;5:1098-106.
4. Brell J, Kalaycio M. Leukemia in pregnancy. Semin Oncol 2000;27:667-77.
5. Su WL, Liu JY, Kao WY. Management of pregnancy-associated acute leukemia. Eur J Gynaecol Oncol 2003;24:251-4.
6. Ali R, Ozkalemkas F, Ozcelik T, et al. Maternal and fetal outcomes in pregnancy complicated with acute leukemia: a single institutional experience with 10 pregnancies at 16 years. Leuk Res 2003;27:381-5.
7. Greenlund LJS, Letendre L, Tefferi A. Acute leukemia during pregnancy: a single institutional experience with 17 cases. Leuk Lymphoma 2001;41:571-7.
8. Garcia L, Valcarcel M, Santiago-Borrero PJ. Chemotherapy during pregnancy and its effects on the fetus-neonatal myelosuppression: two care reports. J Perinatol 1999;29:230-3.
9. Ebert U, Lofflet H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther 1997;74:207-20.
10. Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 1992;152:573-6.
11. Mortishita S, Imai A, Kawabata I, Tamaya T. Acute myelogenous leukemia in pregnancy: fetal blood sampling and early effects of chemotherapy. Int J Gynecol Obstet 1994;44:273-7.
12. O'Donnell R, Costigan C, O'Connell LG. Two cases of acute leukemia in pregnancy. Acta Haematol 1979;61:298-300.
13. Hamer JW, Beard MEJ, Duff GB. Pregnancy complicated by acute myeloid leukemia. N Z Med J 1979;89:212-13.
14. Reynoso EE, Huerta F. Acute leukemia and pregnancy: fatal fetal outcome after exposure to idarubicin during the second trimester. Acta Oncol 1994;33:703-16.
15. Achtari C, Hohlfeld P. Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy. Am J Obstet Oncol 2000;183:511-12.
16. Siu BL, Alonzo MR, Vargo TA, Fenrich AL. Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy. Int J Gynecol Cancer 2002;12:399-402.
17. The AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998;103:100-9.
18. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896-903.
19. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993;81:311-18.
20. Steinmetz HT, Schulz A, Staib P, et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol 1999;78:418-25.
21. Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF, and idarubicin (FLAG-Ida) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia. Br J Haematol 1997;99:939-44.
22. Hoffman JIE, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002;39:1890-900.
23. Brenner JI, Berg KA, Boughman JA. Risk factors for congenital cardiovascular malformations: back to the future. In: Gewitz MH, ed. Primary pediatric cardiology. Armonk, NY: Futura Publishing Company, Inc., 1995:1-24.
24. Simpson LL. Structural cardiac anomalies. Clin Perinatol 2000;27:839-63.
25. Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcomes in 160 patients. Ann Oncol 2004;15:146-50.